

Laguna Hills

Clinical Research Treatment Trial Flowchart

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs

Coord: K. McAbee

Accrual: 5/10

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

CRC: ADJUVANT

NRG GI008/CIRCULATE

(ctDNA guided tx)

PI: Zell

Coord: A. Luna

Accrual: 5/10

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 105/130